Bristol-Myers Squibb | Des Atouts



Assets Changement Date
AbbVie USD 135.16B 8.26B 2024-12
Abbott USD 81.41B 7.06B 2024-12
ALKERMES USD 2.06B 99.72M 2024-12
Amgen USD 91.84B 956M 2024-12
AstraZeneca USD 104.04B 887M 2024-12
Biogen USD 28.05B 263.9M 2024-12
Bristol-Myers Squibb USD 92.6B 1.07B 2024-12
Drreddys Laboratories INR 481.06B 15.1B 2024-12
Eli Lilly USD 78.71B 3.11B 2024-12
Gilead Sciences USD 59B 4.47B 2024-12
GlaxoSmithKline GBP 59.46B 1.41B 2024-12
J&J USD 180.1B 1.82B 2024-12
Medtronic USD 89.97B 69M 2025-01
Merck USD 117.11B 426M 2024-12
Novartis USD 102.25B 1.28B 2024-12
Novo Nordisk 397.44B 28.06B 2024-09
Perrigo USD 9.65B 1.56B 2024-12
Pfizer USD 213.4B 6.08B 2024-12
Prestige Brands USD 3.33B 12.61M 2024-12
Regeneron Pharmaceuticals USD 37.76B 317.5M 2024-12
Roche Holding CHF 101.8B 6.02B 2024-12
Sanofi 129.76B 3.29B 2024-06
Sanofi 129.76B 3.29B 2024-06
United Therapeutics USD 7.36B 240.9M 2024-12
Zoetis USD 14.24B 120M 2024-12



Bristol-Myers Squibb Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2025.